Department of Cardiac Surgery, LMU University Hospital, Munich, Germany.
German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.
Eur J Cardiothorac Surg. 2022 Jun 15;62(1). doi: 10.1093/ejcts/ezac075.
With the expansion of transcatheter aortic valve replacement (TAVR) into intermediate and low risk, the number of TAVR procedures is bound to rise and along with it the number of cases of infective endocarditis following TAVR (TIE). The aim of this study was to review a multicentre experience of patients undergoing surgical intervention for TIE and to analyse the underlying indications and operative results.
We retrospectively identified and analysed 69 patients who underwent cardiac surgery due to TIE at 9 cardiac surgical departments across Germany. The primary outcome was operative mortality, 6-month and 1-year survival.
Median age was 78 years (72-81) and 48(69.6%) were male. The median time to surgical aortic valve replacement was 14 months (5-24) after TAVR, with 32 patients (46.4%) being diagnosed with early TIE. Cardiac reoperations were performed in 17% of patients and 33% underwent concomitant mitral valve surgery. The main causative organisms were: Enterococcus faecalis (31.9%), coagulase-negative Staphylococcus spp. (26.1%), Methicillin-sensitive Staphylococcus aureus (15.9%) and viridians group streptococci (14.5%). Extracorporeal life support was required in 2 patients (2.9%) for a median duration of 3 days. Postoperative adverse cerebrovascular events were observed in 13 patients (18.9%). Postoperatively, 9 patients (13.0%) required a pacemaker and 33 patients (47.8%) needed temporary renal replacement therapy. Survival to discharge was 88.4% and survival at 6 months and 1 year was found to be 68% and 53%, respectively.
Our results suggest that TIE can be treated according to the guidelines for prosthetic valve endocarditis, namely with early surgery. Surgery for TIE is associated with acceptable morbidity and mortality rates. Surgery should be discussed liberally as a treatment option in patients with TIE by the 'endocarditis team' in referral centres.
随着经导管主动脉瓣置换术(TAVR)适应证向中低危人群扩展,TAVR 手术数量势必增加,随之而来的是 TAVR 后感染性心内膜炎(TIE)的病例也会增加。本研究旨在回顾多中心 TIE 患者接受手术治疗的经验,并分析其潜在适应证和手术结果。
我们回顾性地确定并分析了在德国 9 家心脏外科部门因 TIE 接受心脏手术的 69 例患者。主要结局是手术死亡率、6 个月和 1 年生存率。
中位年龄为 78 岁(72-81 岁),48 例(69.6%)为男性。TAVR 后行外科主动脉瓣置换的中位时间为 14 个月(5-24 个月),32 例(46.4%)患者诊断为早期 TIE。17%的患者行心脏再次手术,33%的患者行二尖瓣同期手术。主要病原体为:粪肠球菌(31.9%)、凝固酶阴性葡萄球菌(26.1%)、甲氧西林敏感金黄色葡萄球菌(15.9%)和草绿色链球菌(14.5%)。2 例(2.9%)患者需要体外生命支持,中位时间为 3 天。术后观察到 13 例(18.9%)患者出现不良脑血管事件。术后 9 例(13.0%)需要起搏器,33 例(47.8%)需要临时肾脏替代治疗。出院时生存率为 88.4%,6 个月和 1 年生存率分别为 68%和 53%。
我们的结果表明,TIE 可以根据人工瓣膜心内膜炎的指南进行早期手术治疗。TIE 的手术治疗相关发病率和死亡率可以接受。在转诊中心,由“心内膜炎团队”讨论,应自由地将手术作为 TIE 患者的一种治疗选择。